Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2020. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of September 30, 2020, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital: 5,385,081,188 Ordinary Shares of 25 pence each.
- Treasury Shares: 367,705,950 Ordinary Shares.
- Total Voting Rights: 5,017,375,238.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document is a static notification of capital structure as of a specific date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures beyond the regulatory requirement to notify shareholders of the voting rights denominator.
Investor Verification Checklist
- Verify the total number of voting rights (5,017,375,238) for compliance calculations under FCA rules.
- Confirm the number of shares held in Treasury (367,705,950) to understand the difference between issued capital and voting rights.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for financial metrics.